| 1 | Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. (Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Singareeka Raghavendra A, Yang-Kolodji G, Chu F, Neelapu SS, Marchese A, Hanash S, Zimmermann J, Arteaga CL, Tripathy D) Breast Cancer Res 2023 Jun 06;25(1):62 25 Citations |
| 1 | Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition. (Verma AK, Fatima K, Dudi RK, Tabassum M, Iqbal H, Kumar Y, Luqman S, Mondhe DM, Chanda D, Khan F, Shanker K, Negi AS) Eur J Med Chem 2020 Feb 15;188:111986 10 Citations |
| 1 | Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. (Jain RK, Hong DS, Naing A, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R) Cell Cycle 2015;14(21):3434-40 6 Citations |
| 1 | Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles. (Liu H, Tang X, Srivastava A, Pécot T, Daniel P, Hemmelgarn B, Reyes S, Fackler N, Bajwa A, Kladney R, Koivisto C, Chen Z, Wang Q, Huang K, Machiraju R, Sáenz-Robles MT, Cantalupo P, Pipas JM, Leone G) Nat Cell Biol 2015 Aug;17(8):1036-48 61 Citations |
